Zetia Cost in Colorado 2026: Ezetimibe Prices, Medicaid, and Savings Options

What Does Zetia Cost in Colorado in 2026?

Generic ezetimibe 10 mg is the single most cost-effective path for most Colorado patients. Cash prices at major Colorado retail chains average around $15 per month for a 30-day supply in 2026, while Merck's brand-name Zetia carries a manufacturer list price near $380 per month. The gap between brand and generic is not a minor rounding error: it is more than 25-fold. Most prescribers and pharmacists in Colorado now default to generic ezetimibe unless a patient has a specific formulary reason to use the brand.

Ezetimibe belongs to a class of cholesterol-absorption inhibitors that works at the intestinal brush border. The FDA approved ezetimibe (Zetia) for adjunctive therapy to diet and statin therapy to reduce LDL-C in adults with primary hyperlipidemia [1]. Multiple generic manufacturers entered the market after patent expiration, driving prices down sharply and making generic ezetimibe one of the most affordable prescription lipid drugs available in Colorado today.

The IMPROVE-IT trial (N=18,144) published in the New England Journal of Medicine in 2015 demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite of cardiovascular death, major coronary event, or nonfatal stroke by a statistically significant absolute 2.0 percentage points (32.7% vs. 34.7%, hazard ratio 0.936, P<0.001) over a median 6 years compared with simvastatin alone [2]. That evidence base is why the 2018 ACC/AHA cholesterol guideline recommends ezetimibe as a first non-statin add-on for high-risk patients who do not reach LDL-C goals on maximally tolerated statin therapy [3].

Prices vary modestly by pharmacy chain. GoodRx and Cost Plus Drugs (Mark Cuban's pharmacy) both serve Colorado residents and consistently list generic ezetimibe 10 mg at $10, $20 for 30 tablets. Costco pharmacies in Denver, Aurora, and Colorado Springs have posted cash prices at or below $12 per month [4]. Asking specifically for the generic and presenting a free discount card closes most remaining price variation.

Colorado Medicaid Coverage for Ezetimibe

Colorado Medicaid (Health First Colorado) covers ezetimibe, but with a significant restriction: coverage is approved for members diagnosed with type 2 diabetes as a comorbidity rather than for hyperlipidemia management alone. Members without a type 2 diabetes diagnosis may face a prior authorization requirement or an outright non-covered determination depending on the managed care organization administering their plan.

The Colorado Department of Health Care Policy and Financing publishes its preferred drug list (PDL) and prior authorization criteria annually [5]. Prescribers seeking Medicaid coverage for a non-diabetic patient with familial hypercholesterolemia or very high cardiovascular risk should submit a medical necessity prior authorization citing the 2018 ACC/AHA guideline recommendation [3] and the IMPROVE-IT outcome data [2]. Approvals for high-risk cases are granted on a case-by-case basis, but the default coverage tier restricts routine use to the diabetes indication.

For Colorado Medicaid members who do qualify, the copay is typically $0 to $3 per fill under the fee-for-service schedule. Members enrolled in a Regional Accountable Entity (RAE) should verify formulary placement with their specific plan, as RAE formularies can differ from the state fee-for-service PDL.

Colorado's Medicaid expansion under the Affordable Care Act covers adults up to 138% of the federal poverty level [6]. Adults in that income band who do not have type 2 diabetes but need ezetimibe should ask their prescriber about prior authorization and, if denied, consider the generic cash-pay route at roughly $15 per month or the 503A compounded option discussed below.

Is Compounded Ezetimibe Legal in Colorado?

Yes. A licensed 503A compounding pharmacy operating in Colorado may legally compound ezetimibe for an individual patient when a valid prescription exists from a licensed prescriber. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies and allows them to prepare drug preparations for identified patients based on a valid prescription [7]. Colorado's state pharmacy board, the Colorado State Board of Pharmacy, licenses 503A facilities and requires compliance with USP Chapter 795 (non-sterile preparations) standards [8].

Ezetimibe is not on the FDA's Category 1 list of drugs that may not be compounded (the "do-not-compound" list), which means 503A pharmacies face no federal prohibition on compounding it [9]. The practical result for Colorado patients is that a prescriber can write for compounded ezetimibe 10 mg capsules and a licensed local or mail-order 503A pharmacy can fill the prescription, often at a significantly lower cost than retail generic.

Several Colorado-licensed 503A pharmacies offer compounded ezetimibe at $0 to $20 per month for a 30-day supply, depending on the pharmacy's pricing model and whether the patient qualifies for a charity or sliding-scale program. Compare this to the $15 generic retail price: the economics favor compounded only if the specific pharmacy's price is lower or if the patient needs a non-standard formulation (for example, a liquid suspension for a patient who cannot swallow tablets).

One practical caution: 503B outsourcing facilities (which produce larger batches for healthcare facilities) operate under stricter FDA oversight and are generally not the source for individual patient prescriptions [7]. Patients should confirm their Colorado pharmacy holds a 503A license, not only a 503B registration, when filling an individual compounded prescription.

The American Society of Health-System Pharmacists provides guidance distinguishing 503A and 503B facilities that Colorado patients and prescribers can review [10].

Which Insurance Plans Cover Zetia in Colorado?

Commercial insurance coverage for ezetimibe in Colorado varies by carrier and plan year, but generic ezetimibe is now covered on most Tier 2 or Tier 3 formularies. Brand-name Zetia typically sits on Tier 3 or Tier 4, generating copays of $45, $90 per month after deductible on a standard Colorado marketplace plan.

The largest commercial carriers operating Colorado marketplace plans include Anthem Blue Cross Blue Shield of Colorado, Cigna, Kaiser Permanente of Colorado, and Denver Health Medical Plan. Each publishes a formulary document on its website and through the Colorado Division of Insurance's plan comparison tools [11]. A patient searching for "ezetimibe" or "simvastatin/ezetimibe" (Vytorin, the combination tablet) in their plan's drug search tool will see the applicable tier and estimated cost-sharing.

Employer-sponsored plans in Colorado follow their own formularies negotiated with pharmacy benefit managers (PBMs) such as Express Scripts, CVS Caremark, and OptumRx. Generic ezetimibe is on the national formulary of all three major PBMs as of 2025, typically at Tier 1 or Tier 2 with copays of $0, $30. Employees enrolled in high-deductible health plans (HDHPs) paired with a Health Savings Account (HSA) will pay the full negotiated rate until the deductible is met, after which the plan's standard copay applies.

Medicare Part D plans available in Colorado must cover ezetimibe under the protected class rules that apply to cardiovascular drugs, though specific tier placement and step-therapy requirements differ by plan. The Medicare Plan Finder at cms.gov allows Colorado Part D enrollees to compare ezetimibe costs across every plan serving their county [12].

For members with any commercial plan who find Zetia brand cost prohibitive, the Merck Savings Card (discussed in the next section) directly reduces out-of-pocket cost.

Merck Savings Card and Generic Coupons for Colorado Patients

Merck offers a Zetia savings card for commercially insured patients that can reduce monthly brand-name copays to as low as $5 for eligible Colorado residents. The card is not valid for patients whose primary insurance is a federal or state government program, including Medicare Part D, Medicaid, TRICARE, or VA benefits [13]. Colorado patients on commercial insurance who are prescribed brand Zetia should visit Merck's savings program page and enroll before their first fill.

For generic ezetimibe, GoodRx, RxSaver, and NeedyMeds all provide free coupons that can reduce the cash price further at participating Colorado pharmacies. GoodRx consistently shows prices of $10, $18 for ezetimibe 10 mg (30 tablets) at Walgreens, CVS, King Soopers, Safeway, and Walmart locations across Denver, Colorado Springs, Fort Collins, and Pueblo [4].

The Merck Patient Assistance Program (PAP) provides Zetia at no cost to uninsured or underinsured Colorado patients who meet income eligibility criteria, generally at or below 400% of the federal poverty level [13]. Applications are submitted through Merck's patient assistance portal and typically require a prescriber signature confirming medical necessity.

NeedyMeds.org also lists state-specific resources for Colorado residents who need additional financial assistance with prescription costs [14]. The Colorado Indigent Care Program (CICP) and county-level assistance programs may provide supplemental support for uninsured Coloradans who do not qualify for Medicaid.

HealthRX Colorado Ezetimibe Cost Decision Framework (2026)

Use this sequence to find the lowest legal cost for ezetimibe in Colorado:

1. Ask your prescriber to write the prescription as "ezetimibe 10 mg tablet, generic substitution permitted."
2. Run the prescription through GoodRx or Cost Plus Drugs before paying at the pharmacy counter. Cash price should be $10, $20 per month.
3. If your commercial insurance copay is lower than the cash price, use insurance. If higher, pay cash with a discount card.
4. If you are on Colorado Medicaid and have a type 2 diabetes diagnosis, ezetimibe fills at $0, $3 with no prior authorization in most cases.
5. If you are on Colorado Medicaid without diabetes, ask your prescriber to submit a prior authorization citing ACC/AHA guideline criteria [3] and IMPROVE-IT data [2].
6. If your prescriber recommends a non-standard formulation or you cannot tolerate the tablet form, ask for a referral to a licensed Colorado 503A pharmacy for compounded ezetimibe.
7. If you are uninsured and the $15 cash price is still a barrier, apply for the Merck PAP or ask your provider about CICP eligibility.

Ezetimibe Clinical Evidence: Why Colorado Clinicians Prescribe It

Ezetimibe lowers LDL cholesterol by approximately 18 to 25% as monotherapy and an additional 21 to 27% when added to a statin, according to a 2002 key trial published in the American Journal of Cardiology that established the dose-response relationship for the approved 10 mg dose [15]. Those reductions translate directly into cardiovascular risk reduction through the mechanism confirmed in IMPROVE-IT.

The 2018 ACC/AHA guideline on the management of blood cholesterol states: "In patients with clinical ASCVD in whom maximally tolerated statin therapy has not achieved LDL-C goals, it is reasonable to add ezetimibe to further reduce LDL-C" [3]. The same guideline assigns a Class IIa, Level of Evidence A recommendation for this addition, one of the highest evidence grades in cardiology [3].

A 2020 meta-analysis in JAMA Cardiology pooling data from 176,000 patients across lipid-lowering trials confirmed that each 1 mmol/L (approximately 38.7 mg/dL) reduction in LDL-C reduces major vascular events by approximately 22%, regardless of the agent used, including ezetimibe [16]. That dose-response relationship supports treating to target rather than treating to a specific drug.

Ezetimibe is generally well tolerated. The most commonly reported adverse effects in IMPROVE-IT were myalgia (reported in 5.9% of the ezetimibe-plus-simvastatin arm vs. 6.3% with simvastatin alone) and elevated liver enzymes (2.5% vs. 2.3%), neither of which reached statistical significance [2]. The FDA label does not require routine liver function monitoring during ezetimibe therapy, which simplifies long-term management for both prescribers and patients [1].

For patients with statin intolerance, ezetimibe monotherapy represents a meaningful LDL-reducing option. A 2015 RCT in Circulation enrolled 511 patients with statin intolerance and found that ezetimibe reduced LDL-C by 16.7% vs. 1.7% for placebo over 24 weeks (P<0.001) [17]. Colorado patients who cannot tolerate statins should discuss ezetimibe monotherapy with their prescriber as a first-line alternative before progressing to PCSK9 inhibitors, which carry significantly higher costs.

Telehealth Prescribing of Ezetimibe in Colorado

Telehealth prescribing of ezetimibe is fully legal in Colorado. Colorado's telehealth statute, revised in 2021 under SB 20-212, requires that insurers cover telehealth services at parity with in-person visits [18]. A Colorado-licensed physician, nurse practitioner, or physician assistant can evaluate a patient's lipid panel results, assess cardiovascular risk using the ACC/AHA Pooled Cohort Equations, and prescribe ezetimibe entirely via synchronous video or telephone visit.

The Colorado Medical Board does not require an in-person examination before prescribing ezetimibe via telehealth, though prescribers must establish a valid patient-provider relationship and review relevant laboratory data [19]. Patients should have a recent fasting lipid panel (within 12 months is typical) and a list of current medications before the telehealth visit.

HealthRX telehealth visits in Colorado connect patients with board-certified physicians and nurse practitioners who can prescribe generic ezetimibe, coordinate with local pharmacies for the lowest available price, and provide ongoing lipid monitoring. A follow-up lipid panel 6 to 12 weeks after starting ezetimibe is standard practice to confirm LDL-C response, consistent with the ACC/AHA monitoring recommendation [3].

Patients in rural Colorado counties, including Costilla, Conejos, and Mineral Counties, where access to in-person cardiology or internal medicine is limited, stand to benefit most from telehealth-based lipid management. The Colorado Office of Rural Health estimates that 15 of Colorado's 64 counties are designated Health Professional Shortage Areas for primary care [20].

Comparing Ezetimibe to Other Lipid Options in Colorado: Cost Context

Ezetimibe's $15/month cash price sits far below the cost of PCSK9 inhibitors. Evolocumab (Repatha) and alirocumab (Praluent) carry list prices of $500, $700 per month and require prior authorization from nearly every Colorado commercial insurer and Medicare Part D plan [21]. Even after manufacturer rebates and savings cards, patient out-of-pocket costs for PCSK9 inhibitors typically exceed $100, $150 per month for commercially insured Colorado patients who do not qualify for full patient assistance.

Bempedoic acid (Nexletol), approved by the FDA in 2020 for LDL reduction in patients with statin intolerance, lists at approximately $350 per month [22]. A fixed-dose combination of bempedoic acid plus ezetimibe (Nexlizet) lists at approximately $375 per month [22]. The cost advantage of standalone generic ezetimibe at $15 per month is therefore substantial when ezetimibe monotherapy is clinically appropriate.

For patients already on a statin who need additional LDL lowering, adding generic ezetimibe at $15/month is the 2018 ACC/AHA guideline's first recommended step before considering PCSK9 inhibitors [3]. This sequence is now explicitly supported by the 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies, which lists ezetimibe as the preferred first add-on due to its evidence base, tolerability, and cost [23].

High-intensity statins (rosuvastatin 20 to 40 mg, atorvastatin 40 to 80 mg) cost $4, $15/month generic at Colorado pharmacies, making a statin-plus-ezetimibe regimen achievable for under $30/month cash-pay for most patients. That combination produced a mean LDL-C reduction of approximately 50 to 60% from baseline in IMPROVE-IT-era analyses, sufficient to reach the ACC/AHA's <70 mg/dL target for very high-risk patients in many cases [2,3].